Autologous Anti-CD3/Anti-EGFR Bispecific Antibody Armed Peripheral Blood Mononuclear Cells

**Semantic type:** Cell|Pharmacologic Substance

**Definition:** A preparation of autologous peripheral blood mononuclear cells (PBMCs) in which T-lymphocytes are coated with a bispecific antibody directed against the tumor-associated antigen (TAA) human epidermal growth factor receptor (EGFR; HER1; ErbB1) and the T-cell surface antigen CD3 and activated ex vivo, with potential immunomodulating and antineoplastic activities. Upon reintroduction into the patient, the autologous anti-CD3/anti-EGFR bispecific antibody armed PBMCs target, bind to and selectively cross-link CD3-expressing T-cells and EGFR-expressing tumor cells. This results in the activation of cytotoxic T-lymphocytes (CTLs) and selective cytotoxicity towards the EGFR-expressing tumor cells. EGFR, a receptor tyrosine kinase, is overexpressed on the surfaces of various tumor cell types.

**Synonyms:** - Autologous Anti-CD3/Anti-EGFR Bispecific Antibody Armed PBMCs - Autologous Anti-CD3/EGFR Bispecific Antibody Armed PBMCs - Autologous Anti-EGFR/Anti-CD3 Bispecific Antibody Armed PBMCs - Autologous CD3 x EGFR Bispecific Antibody Armed PBMCs - EGFR FPBMC - EGFR Fresh PBMC - EGFRBi Armed Fresh PBMC